Subtopic Deep Dive

← Glycosylation and Glycoproteins Research

Glycosylation in Cancer
Research Guide

What is Glycosylation in Cancer?

Glycosylation in cancer examines tumor-associated glycan alterations, including sialylation and fucosylation changes, that promote immune evasion and cancer progression.

Tumor cells exhibit aberrant glycosylation patterns, such as increased sialylation and fucosylation, detected via glycoproteomic profiling (Pinho and Reis, 2015; 2967 citations). These changes alter protein function, including CD44 and HER-2 glycoproteins, influencing metastasis and therapy response. Over 10 papers from 2009-2019 in the list address mechanisms and biomarkers.

Curated Papers

Key Challenges

Why It Matters

Altered glycosylation in cancer enables immune evasion through galectin-glycan interactions, as shown by Rabinovich and Toscano (2009; 885 citations), supporting glycan-based immunotherapies. Glycoproteomic changes in CD44 identify cancer stem cell biomarkers for targeted treatments (Yan et al., 2015; 625 citations). HER-2 glycosylation impacts trastuzumab efficacy in breast cancer diagnostics (Ross et al., 2009; 1139 citations), guiding personalized medicine.

Key Research Challenges

Heterogeneity of glycan structures

Tumor glycan profiles vary across cancer types and stages, complicating biomarker identification (Pinho and Reis, 2015). Glycoproteomic methods struggle with detecting low-abundance sialylated structures (Stowell et al., 2015). Christiansen et al. (2013; 514 citations) highlight challenges in profiling cell surface glycoproteins.

Linking glycans to immune evasion

Mechanisms connecting fucosylation to immune tolerance remain unclear (Rabinovich and Toscano, 2009). O-GlcNAc modifications regulate cancer signaling but lack causal models (Bond and Hanover, 2015; 564 citations). Reily et al. (2019; 2008 citations) note gaps in glycan-disease causality.

Therapeutic targeting difficulties

Glycan alterations on HER-2 reduce antibody efficacy, requiring new targeting strategies (Ross et al., 2009). Nanobody and scFv approaches face glycosylation shielding issues (Jovčevska and Muyldermans, 2019; 723 citations; Ahmad et al., 2012; 721 citations). Developing glycan-specific diagnostics lags behind proteomics.

Essential Papers

Glycosylation in cancer: mechanisms and clinical implications

Salomé S. Pinho, Celso A. Reis · 2015 · Nature reviews. Cancer · 3.0K citations

Glycosylation in health and disease

Colin Reily, Tyler J. Stewart, Matthew B. Renfrow et al. · 2019 · Nature Reviews Nephrology · 2.0K citations

The biology and role of CD44 in cancer progression: therapeutic implications

Chen Chen, Shujie Zhao, Anand B. Karnad et al. · 2018 · Journal of Hematology & Oncology · 1.4K citations

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Jeffrey S. Ross, Elzbieta Slodkowska, W. Fraser Symmans et al. · 2009 · The Oncologist · 1.1K citations

Learning Objectives Contrast the current strengths and limitations of the three main slide-based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer tissues for HER...

Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation

Gabriel A. Rabinovich, Marta A. Toscano · 2009 · Nature reviews. Immunology · 885 citations

Protein Glycosylation in Cancer

Sean R. Stowell, Tongzhong Ju, Richard D. Cummings · 2015 · Annual Review of Pathology Mechanisms of Disease · 861 citations

Neoplastic transformation results in a wide variety of cellular alterations that impact the growth, survival, and general behavior of affected tissue. Although genetic alterations underpin the deve...

The Therapeutic Potential of Nanobodies

Ivana Jovčevska, Serge Muyldermans · 2019 · BioDrugs · 723 citations

Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementa...

Reading Guide

Foundational Papers

Start with Pinho and Reis (2015; 2967 citations) for mechanisms overview, then Ross et al. (2009; 1139 citations) for HER-2 glycosylation in therapy, and Rabinovich and Toscano (2009; 885 citations) for immune interactions.

Recent Advances

Study Reily et al. (2019; 2008 citations) for disease-wide glycosylation, Yan et al. (2015; 625 citations) for CD44 stem cells, and Bond and Hanover (2015; 564 citations) for O-GlcNAc.

Core Methods

Core techniques include glycoproteomic profiling (Christiansen et al., 2013), scFv antibody engineering for glycan targeting (Ahmad et al., 2012), and nanobody therapies (Jovčevska and Muyldermans, 2019).

How PapersFlow Helps You Research Glycosylation in Cancer

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map high-citation works like Pinho and Reis (2015; 2967 citations), then findSimilarPapers reveals related sialylation studies. exaSearch uncovers niche glycoproteomic biomarkers from 250M+ OpenAlex papers.

Analyze & Verify

Analysis Agent applies readPaperContent to extract glycan mechanisms from Stowell et al. (2015), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis for statistical meta-analysis of citation impacts or O-GlcNAc signaling data using pandas. GRADE grading scores evidence strength for therapeutic claims.

Synthesize & Write

Synthesis Agent detects gaps in immune evasion literature via galectin-glycan papers, flags contradictions between CD44 studies. Writing Agent uses latexEditText, latexSyncCitations for HER-2 review sections, and latexCompile to generate polished manuscripts with exportMermaid for glycan pathway diagrams.

Use Cases

"Analyze glycosylation changes in breast cancer HER-2 from recent papers"

Research Agent → searchPapers('HER-2 glycosylation cancer') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of sialylation data) → statistical verification of biomarker correlations output.

"Write LaTeX review on sialylation immune evasion in tumors"

Synthesis Agent → gap detection(citationGraph on Pinho 2015) → Writing Agent → latexEditText + latexSyncCitations(Rabinovich 2009) → latexCompile → formatted PDF with glycan diagrams.

"Find code for glycoproteomic analysis in cancer papers"

Research Agent → paperExtractUrls(Stowell 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox for glycan profiling scripts output.

Automated Workflows

Deep Research workflow scans 50+ glycosylation papers via citationGraph from Pinho and Reis (2015), producing structured biomarker reports with GRADE scores. DeepScan applies 7-step CoVe to verify O-GlcNAc claims (Bond and Hanover, 2015), checkpointing glycoproteomic data. Theorizer generates hypotheses on CD44 glycan roles in stem cells from Yan et al. (2015).

Try Doxa for Glycosylation in Cancer Research

Frequently Asked Questions

What defines glycosylation in cancer?

Glycosylation in cancer involves tumor-specific glycan changes like hypersialylation and fucosylation that promote progression and evasion (Pinho and Reis, 2015).

What methods study cancer glycans?

Glycoproteomic profiling and mass spectrometry detect alterations on proteins like CD44 and HER-2 (Stowell et al., 2015; Christiansen et al., 2013).

What are key papers?

Pinho and Reis (2015; 2967 citations) reviews mechanisms; Stowell et al. (2015; 861 citations) details protein glycosylation; Ross et al. (2009; 1139 citations) covers HER-2.

What open problems exist?

Challenges include causal links between glycans and metastasis, scalable glycan therapeutics, and heterogeneity across tumors (Reily et al., 2019; Bond and Hanover, 2015).